Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BCHE | P06276 | 8/20 | 0.69 |
| ▸ | ACHE | P22303 | 6/20 | 0.69 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.68 |
| ▸ | RARB | P10826 | 3/20 | 0.64 |
| ▸ | XDH | P47989 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470619 | 1.00 | ABCG2 (0.76) | ABCG2TP53TSHRBCHEACHE | |
| SCHEMBL1470590 | 1.00 | ABCG2 (0.76) | ABCG2TP53TSHRBCHEACHE | |
| SCHEMBL1470618 | 1.00 | ABCG2 (0.76) | ABCG2TP53TSHRBCHEACHE | |
| SCHEMBL27946959 | 0.91 | NPC1 (0.75) | ABCG2BCHEACHE | |
| SCHEMBL9649614 | 0.89 | TP53 (0.82) | ABCG2TP53TSHRPLA2G4BRARB | |
| SCHEMBL9649608 | 0.89 | TP53 (0.82) | ABCG2TP53TSHRPLA2G4BRARB | |
| SCHEMBL5692920 | 0.89 | TP53 (0.82) | ABCG2TP53TSHRPLA2G4BRARB | |
| SCHEMBL14984230 | 0.89 | TP53 (0.82) | ABCG2TP53TSHRPLA2G4BRARB | |
| SCHEMBL14984232 | 0.89 | TP53 (0.82) | ABCG2TP53TSHRPLA2G4BRARB | |
| SCHEMBL1702614 | 0.88 | ABCG2 (0.92) | ABCG2BCHEACHEXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-2182405-B1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR PRODUCING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORP (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2182406-B1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR FORMING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8399068-B2 | Liquid crystal aligning agent, method of producing a liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8304031-B2 | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8216649-B2 | Liquid crystal aligning agent, method of producing a liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110118422-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD OF PRODUCING A LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110105700-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110068301-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD OF PRODUCING A LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2182405-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR PRODUCING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2182406-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR FORMING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2182407-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR PRODUCING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885TP53 2914/4885TSHR 3540/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885TP53 3452/4885TSHR 3089/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885TP53 3452/4885TSHR 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.